NZ706232A - Anti-cd3 antibodies and uses thereof - Google Patents

Anti-cd3 antibodies and uses thereof

Info

Publication number
NZ706232A
NZ706232A NZ706232A NZ70623213A NZ706232A NZ 706232 A NZ706232 A NZ 706232A NZ 706232 A NZ706232 A NZ 706232A NZ 70623213 A NZ70623213 A NZ 70623213A NZ 706232 A NZ706232 A NZ 706232A
Authority
NZ
New Zealand
Prior art keywords
antigen
human
complementarity determining
bind
determining regions
Prior art date
Application number
NZ706232A
Other languages
English (en)
Inventor
Nicholas Papadopoulos
Eric Smith
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49304338&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ706232(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Priority to NZ742078A priority Critical patent/NZ742078A/en
Publication of NZ706232A publication Critical patent/NZ706232A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Liquid Crystal Substances (AREA)
  • Prostheses (AREA)
  • Secondary Cells (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NZ706232A 2012-09-21 2013-09-19 Anti-cd3 antibodies and uses thereof NZ706232A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ742078A NZ742078A (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261704029P 2012-09-21 2012-09-21
US201361753461P 2013-01-17 2013-01-17
US201361763110P 2013-02-11 2013-02-11
US201361827098P 2013-05-24 2013-05-24
PCT/US2013/060511 WO2014047231A1 (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Publications (1)

Publication Number Publication Date
NZ706232A true NZ706232A (en) 2018-11-30

Family

ID=49304338

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ706232A NZ706232A (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies and uses thereof
NZ742078A NZ742078A (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ742078A NZ742078A (en) 2012-09-21 2013-09-19 Anti-cd3 antibodies, bispecific antigen-binding molecules that bind cd3 and cd20, and uses thereof

Country Status (34)

Country Link
US (5) US9657102B2 (enExample)
EP (3) EP2897981B1 (enExample)
JP (7) JP6923292B2 (enExample)
KR (2) KR102470709B1 (enExample)
CN (3) CN113980132B (enExample)
AR (1) AR092612A1 (enExample)
AU (3) AU2013318059C1 (enExample)
BR (1) BR112015005380B1 (enExample)
CA (3) CA3253502A1 (enExample)
CL (3) CL2015000713A1 (enExample)
CO (1) CO7400860A2 (enExample)
DK (2) DK3778641T5 (enExample)
EA (1) EA033400B1 (enExample)
ES (2) ES2968913T3 (enExample)
FI (2) FI3778641T3 (enExample)
HR (2) HRP20230844T1 (enExample)
HU (2) HUE065481T2 (enExample)
IL (2) IL237301B (enExample)
JO (3) JOP20200236A1 (enExample)
LT (2) LT2897981T (enExample)
MX (2) MX373931B (enExample)
MY (1) MY179577A (enExample)
NZ (2) NZ706232A (enExample)
PH (2) PH12019502070B1 (enExample)
PL (2) PL2897981T3 (enExample)
PT (2) PT3778641T (enExample)
RS (2) RS64378B1 (enExample)
SG (3) SG11201501269XA (enExample)
SI (2) SI2897981T1 (enExample)
SM (2) SMT202300456T1 (enExample)
TW (4) TWI697502B (enExample)
UY (1) UY35042A (enExample)
WO (1) WO2014047231A1 (enExample)
ZA (2) ZA201501097B (enExample)

Families Citing this family (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101463631B1 (ko) 2006-03-31 2014-11-19 추가이 세이야쿠 가부시키가이샤 항체의 혈중 동태를 제어하는 방법
RU2510400C9 (ru) 2007-09-26 2014-07-20 Чугаи Сейяку Кабусики Кайся Способ модификации изоэлектрической точки антитела с помощью аминокислотных замен в cdr
ES2693232T3 (es) 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Agente terapéutico que induce citotoxicidad
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP6444874B2 (ja) 2012-10-08 2018-12-26 ロシュ グリクアート アーゲー ２つのＦａｂフラグメントを含むＦｃ不含抗体および使用方法
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
CA3211863A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
PE20151410A1 (es) 2013-02-26 2015-09-18 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
WO2014131694A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
EP3024851B1 (en) 2013-07-25 2018-05-09 CytomX Therapeutics, Inc. Multispecific antibodies, multispecific activatable antibodies and methods of using the same
PT3083689T (pt) 2013-12-17 2020-08-27 Genentech Inc Anticorpos anti-cd3 e métodos de utilização
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
EP3105252B1 (en) 2014-02-12 2019-07-24 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
BR112016022385A2 (pt) 2014-03-28 2018-06-19 Xencor, Inc anticorpos específicos que se ligam a cd38 e cd3
CN106459213B (zh) 2014-04-03 2020-12-01 Igm生物科学股份有限公司 修饰的j链
CN106459206B (zh) 2014-04-07 2024-06-07 中外制药株式会社 免疫活化抗原结合分子
MX2016014434A (es) * 2014-05-13 2017-02-23 Chugai Pharmaceutical Co Ltd Molecula de union a antigeno redirigida a celulas t para celulas que tienen funcion de inmunosupresion.
US10669337B2 (en) * 2014-07-25 2020-06-02 Cytomx Therapeutics, Inc. Bispecific anti-CD3 antibodies, bispecific activatable anti-CD3 antibodies, and methods of using the same
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
WO2016019969A1 (en) 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
PE20170670A1 (es) 2014-09-12 2017-06-06 Genentech Inc Anticuerpos anti-cll-1 e inmunoconjugados
WO2016054101A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
WO2016077720A1 (en) * 2014-11-14 2016-05-19 Protein One, Llc Binding agents and uses thereof
ES2809455T3 (es) 2014-11-17 2021-03-04 Regeneron Pharma Métodos para tratamiento tumoral usando anticuerpo biespecífico CD3xCD20
WO2016079076A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules agiant folr1 and cd3
PT3221357T (pt) 2014-11-20 2020-07-28 Hoffmann La Roche Cadeias leves comuns e métodos de utilização
LT3221355T (lt) 2014-11-20 2020-12-28 F. Hoffmann-La Roche Ag Kombinuotoji t ląsteles aktyvinančių bispecifinių antigeną surišančių molekulių cd3 bei folato receptoriaus 1 (folr1) ir pd-1 ašą surišančių antagonistų terapija
RS63410B1 (sr) 2014-11-24 2022-08-31 Regeneron Pharma Ne-humane životinje koje eksprimiraju humanizovani cd3 kompleks
WO2016086189A2 (en) * 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and tumor antigens
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
SG11201704274QA (en) 2014-11-26 2017-06-29 Xencor Inc Heterodimeric antibodies that bind cd3 and cd38
LT3227336T (lt) 2014-12-05 2019-09-25 F. Hoffmann-La Roche Ag Anti-cd79b antikūnai ir jų naudojimo būdai
US20170058043A1 (en) 2014-12-06 2017-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
EP3546567A1 (en) 2014-12-06 2019-10-02 GEMoaB Monoclonals GmbH Genetic modified pluri- or multipotent stem cells and uses thereof
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
US10544220B2 (en) * 2015-01-08 2020-01-28 Genmab A/S Bispecific antibodies against CD3 and CD20
KR20220018081A (ko) * 2015-03-04 2022-02-14 아이쥐엠 바이오사이언스 인코포레이티드 Ｃｄ20 결합 분자 및 그의 용도
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3271022A4 (en) 2015-03-19 2018-10-31 Duke University Hiv-1 neutralizing antibodies and uses thereof
US10344077B2 (en) 2015-03-19 2019-07-09 Duke University HIV-1 neutralizing antibodies and uses thereof (V3 antibodies)
WO2016149710A2 (en) 2015-03-19 2016-09-22 Duke University Hiv-1 neutralizing antibodies and uses thereof
WO2016149695A1 (en) 2015-03-19 2016-09-22 Duke University HIV-1 NEUTRALIZING ANTIBODIES AND USES THEREOF (CD4bs ANTIBODIES)
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
CN115536750A (zh) * 2015-05-08 2022-12-30 森科股份有限公司 结合cd3和肿瘤抗原的异二聚体抗体
EA039429B1 (ru) * 2015-05-13 2022-01-26 Ридженерон Фармасьютикалз, Инк. Способы лечения опухолей с применением биспецифического антитела cd3xcd20
SG10202002131PA (en) 2015-05-21 2020-05-28 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
EP3303400B1 (en) 2015-05-28 2020-09-09 Genentech, Inc. Cell-based assay for detecting anti-cd3 homodimers
CN104931699A (zh) * 2015-05-29 2015-09-23 北京海思特临床检验所有限公司 骨髓涂片异常淋巴细胞染色试剂盒及其使用方法
CA2988768A1 (en) * 2015-06-09 2016-12-15 Memorial Sloan Kettering Cancer Center T cell receptor-like antibody agents specific for ebv latent membrane protein 2a peptide presented by human hla
EP3310814B1 (en) 2015-06-16 2023-08-02 F. Hoffmann-La Roche AG Humanized and affinity matured antibodies to fcrh5 and methods of use
TW201718647A (zh) 2015-06-16 2017-06-01 建南德克公司 抗-cll-1抗體及使用方法
WO2016207240A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Anti-transferrin receptor antibodies with tailored affinity
US20180201693A1 (en) * 2015-07-09 2018-07-19 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
JOP20160154B1 (ar) * 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI870789B (zh) 2015-08-04 2025-01-21 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
BR112018005573A2 (pt) 2015-09-21 2019-01-22 Aptevo Research And Development Llc ?polipeptídeos de ligação a cd3?
EA201890785A1 (ru) * 2015-09-23 2018-10-31 Ридженерон Фармасьютикалз, Инк. Оптимизированные биспецифические анти-cd3 антитела и их применение
JP7058213B2 (ja) 2015-09-30 2022-04-21 アイジーエム バイオサイエンシズ インコーポレイテッド 改変ｊ鎖を有する結合分子
WO2017059380A1 (en) 2015-09-30 2017-04-06 Igm Biosciences, Inc. Binding molecules with modified j-chain
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114057884A (zh) 2015-10-02 2022-02-18 豪夫迈·罗氏有限公司 双特异性抗人cd20/人转铁蛋白受体抗体及使用方法
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
TWI756187B (zh) 2015-10-09 2022-03-01 美商再生元醫藥公司 抗ｌａｇ３抗體及其用途
HRP20211528T1 (hr) 2015-10-25 2021-12-24 Sanofi Trispecifični i/ili trovalentni vezujući proteini za prevenciju ili liječenje hiv infekcije
WO2017086419A1 (ja) * 2015-11-18 2017-05-26 中外製薬株式会社 液性免疫応答の増強方法
JP6931329B2 (ja) * 2015-11-18 2021-09-01 中外製薬株式会社 免疫抑制機能を有する細胞に対するｔ細胞リダイレクト抗原結合分子を用いた併用療法
CN106810611A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗cMet和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CN106810610A (zh) * 2015-11-30 2017-06-09 中国科学院深圳先进技术研究院 抗EpCAM和CD3特异性双靶向抗体及其制备方法和应用、含该双靶向抗体表达盒的微环DNA及应用
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
MX2018005229A (es) 2015-12-09 2019-04-29 F Hoffmann­La Roche Ag Anticuerpo anti-cd20 de tipo ii y usos del mismo.
JP7126941B2 (ja) 2015-12-22 2022-08-29 リジェネロン・ファーマシューティカルズ・インコーポレイテッド がんを治療するための抗ｐｄ－１抗体と二重特異性抗ｃｄ２０／抗ｃｄ３抗体の組合せ
PL3400246T3 (pl) 2016-01-08 2021-03-08 F. Hoffmann-La Roche Ag Sposoby leczenia nowotworów z dodatnim markerem cea z wykorzystaniem antagonistów wiążących oś pd-1 oraz przeciwciał dwuswoistych anty-cea/anty-cd3
CN109073635A (zh) 2016-01-25 2018-12-21 豪夫迈·罗氏有限公司 用于测定t细胞依赖性双特异性抗体的方法
MY195542A (en) 2016-02-03 2023-01-31 Amgen Res Munich Gmbh Psma and CD3 Bispecific T Cell Engaging Antibody Constructs
CA3016424A1 (en) * 2016-03-14 2017-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
ES2947230T3 (es) 2016-03-22 2023-08-03 Hoffmann La Roche Moléculas biespecíficas para linfocitos T activadas por proteasa
SG11201808911SA (en) * 2016-04-13 2018-11-29 Sanofi Sa Trispecific and/or trivalent binding proteins
DK3443006T5 (da) 2016-04-13 2024-09-16 Sanofi Sa Trispecifikke og/eller trivalente bindingsproteiner
EP3445781A1 (en) 2016-04-20 2019-02-27 Regeneron Pharmaceuticals, Inc. Compositions and methods for making antibodies based on use of expression-enhancing loci
SG10202010156XA (en) 2016-04-20 2020-11-27 Regeneron Pharma Compositions and methods for making antibodies based on use of an expression-enhancing locus
TWI822521B (zh) 2016-05-13 2023-11-11 美商再生元醫藥公司 藉由投予pd-1抑制劑治療皮膚癌之方法
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
HUE072731T2 (hu) * 2016-05-20 2025-12-28 Harpoon Therapeutics Inc Egyszeres láncú variábilis fragmentumú CD3-kötõ proteinek
AU2017268460B2 (en) 2016-05-20 2023-12-14 Harpoon Therapeutics, Inc. Single domain serum albumin binding protein
US10865230B2 (en) * 2016-05-27 2020-12-15 Altor Bioscience, Llc Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
CN110603266A (zh) 2016-06-02 2019-12-20 豪夫迈·罗氏有限公司 用于治疗癌症的ii型抗cd20抗体和抗cd20/cd3双特异性抗体
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
CA3026151A1 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
RU2769282C2 (ru) 2016-06-20 2022-03-30 Кимаб Лимитед Анти-PD-L1 и IL-2 цитокины
EP3471773A4 (en) * 2016-06-21 2020-07-08 Teneobio, Inc. ANTIBODIES BINDING CD3
CN109689692B (zh) 2016-06-22 2021-11-12 本康生物制药（深圳）有限公司 用于肿瘤治疗的双特异性抗体和抗体偶联物及其应用
KR20190020341A (ko) 2016-06-28 2019-02-28 젠코어 인코포레이티드 소마토스타틴 수용체 2에 결합하는 이종이량체 항체
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
CN115404196A (zh) 2016-07-13 2022-11-29 哈佛学院院长等 抗原呈递细胞模拟支架及其制备和使用方法
WO2018034885A1 (en) * 2016-08-16 2018-02-22 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
CN106317226B (zh) * 2016-08-19 2017-09-05 安源医药科技（上海）有限公司 用于构建融合蛋白的连接肽
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
SI4050034T1 (sl) 2016-09-14 2024-07-31 Teneoone, Inc. Protitelesa, ki se vežejo na CD3
US10772972B2 (en) 2016-09-23 2020-09-15 Regeneron Pharmaceuticals, Inc. Anti-STEAP2 antibody drug conjugates, and compositions and uses thereof
HRP20231281T1 (hr) 2016-09-23 2024-02-02 Regeneron Pharmaceuticals, Inc. Bispecifična anti-muc16-cd3 antitijela i konjugati anti-muc16 s lijekom
WO2018064611A1 (en) * 2016-09-30 2018-04-05 Baylor College Of Medicine Antibody based gene therapy with tissue-directed expression
JP7022123B2 (ja) 2016-09-30 2022-02-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３に対する二重特異性抗体
PE20240950A1 (es) 2016-10-14 2024-05-06 Xencor Inc PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa)
JP7784795B2 (ja) 2016-11-15 2025-12-12 ジェネンテック， インコーポレイテッド 抗ｃｄ２０／抗ｃｄ３二重特異性抗体による処置のための投与
CA3044729A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Psma targeting trispecific proteins and methods of use
KR20210087108A (ko) 2016-11-23 2021-07-09 하푼 테라퓨틱스, 인크. 전립선 특이 막 항원 결합 단백질
US20180193003A1 (en) 2016-12-07 2018-07-12 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
KR102660715B1 (ko) 2017-02-10 2024-04-26 리제너론 파마슈티칼스 인코포레이티드 면역-pet 이미지화를 위한 방사선 라벨링된 항-lag3 항체
CN117442719A (zh) 2017-02-21 2024-01-26 瑞泽恩制药公司 用于治疗肺癌的抗pd-1抗体
US11459394B2 (en) 2017-02-24 2022-10-04 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US11492399B2 (en) * 2017-03-24 2022-11-08 Zenyaku Kogyo Co., Ltd. Anti-IgM/B cell surface antigen bispecific antibody
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
WO2018209298A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
CN115028727A (zh) 2017-05-12 2022-09-09 哈普恩治疗公司 靶向msln的三特异性蛋白质及使用方法
EP3409322A1 (en) 2017-06-01 2018-12-05 F. Hoffmann-La Roche AG Treatment method
MX2019015563A (es) 2017-06-20 2020-07-28 Teneoone Inc Anticuerpos anti-bcma unicamente de cadena pesada.
IL312322A (en) 2017-06-20 2024-06-01 Teneobio Inc Anti-BCMA antibodies containing only heavy chains
AU2018291497A1 (en) 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
MX2020000228A (es) 2017-07-06 2020-08-10 Regeneron Pharma Proceso de cultivo celular para producir una glicoproteina.
EP3676294A4 (en) * 2017-08-28 2021-12-22 Systimmune, Inc. ANTI-CD3 ANTIBODIES AND METHOD OF MANUFACTURING AND USING THEREOF
US20200268795A1 (en) * 2017-09-22 2020-08-27 The Regents Of The University Of California Interferon-gamma attenuates anti-tumor immune response to checkpoint blockade
CA3076632A1 (en) * 2017-09-29 2019-04-04 Regeneron Pharmaceuticals, Inc. Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof
LT3694529T (lt) 2017-10-13 2024-10-10 Harpoon Therapeutics, Inc. Trispecifiniai baltymai ir panaudojimo būdai
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
EP3694885A1 (en) 2017-10-14 2020-08-19 CytomX Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
KR101973060B1 (ko) * 2017-10-20 2019-04-26 주식회사 녹십자 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
WO2019125732A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
CN115925882A (zh) 2017-12-22 2023-04-07 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
JP7486421B2 (ja) 2017-12-22 2024-05-17 テネオバイオ， インコーポレイテッド Ｃｄ２２に結合する重鎖抗体
CN111655722A (zh) 2018-01-31 2020-09-11 瑞泽恩制药公司 用于表征药物产品杂质的系统和方法
TWI786265B (zh) 2018-02-02 2022-12-11 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
SG11202007390YA (en) 2018-02-08 2020-08-28 Genentech Inc Bispecific antigen-binding molecules and methods of use
EP3749360A1 (en) 2018-02-09 2020-12-16 Genmab A/S Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
CA3088906A1 (en) 2018-02-28 2019-09-06 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
CN111868085B (zh) 2018-03-19 2024-11-05 瑞泽恩制药公司 微芯片毛细管电泳测定法及试剂
US12253490B2 (en) 2018-03-19 2025-03-18 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
US12259355B2 (en) 2018-03-19 2025-03-25 Regeneron Pharmaceuticals, Inc. Microchip capillary electrophoresis assays and reagents
WO2019195623A2 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112867734A (zh) 2018-04-18 2021-05-28 Xencor股份有限公司 包含IL-15/IL-15Ra Fc融合蛋白和PD-1抗原结合结构域的靶向PD-1的异源二聚体融合蛋白及其用途
US11505595B2 (en) 2018-04-18 2022-11-22 Xencor, Inc. TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15RA Fc-fusion proteins and TIM-3 antigen binding domains
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
JP2021523192A (ja) 2018-05-14 2021-09-02 ハープーン セラピューティクス，インク． 免疫グロブリン分子の条件的活性化のための結合部分
DK3802608T3 (da) * 2018-05-24 2025-06-10 Janssen Biotech Inc Anti-cd3-antistoffer og anvendelser deraf
CN110540593B (zh) * 2018-05-29 2022-05-17 上海药明生物技术有限公司 新型的抗cd3/抗cd20双特异性抗体
US12227565B2 (en) 2018-06-20 2025-02-18 Biora Therapeutics, Inc. Method of formulating a pharmaceutical composition comprising administering an immune modulator to the small intestine
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
CA3104098A1 (en) 2018-06-21 2019-12-26 Regeneron Pharmaceuticals, Inc. Bispecific anti-psma x anti-cd28 antibodies and uses thereof
TWI838389B (zh) * 2018-07-19 2024-04-11 美商再生元醫藥公司 雙特異性抗-BCMAｘ抗-CD3抗體及其用途
JP7404335B2 (ja) 2018-07-19 2023-12-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｂｃｍａ特異性を有するキメラ抗原受容体およびその使用
MX2021002165A (es) 2018-08-23 2021-07-16 Regeneron Pharma Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de éstos.
JP2021535739A (ja) 2018-08-27 2021-12-23 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 下流精製でのラマン分光法の使用
KR20210053816A (ko) 2018-08-30 2021-05-12 리제너론 파마슈티칼스 인코포레이티드 단백질 복합체를 특성화하기 위한 방법
JP7605734B2 (ja) * 2018-08-31 2024-12-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３／ｃ２０二重特異性抗体のサイトカイン放出症候群を軽減する投与戦略
WO2020061482A1 (en) 2018-09-21 2020-03-26 Harpoon Therapeutics, Inc. Egfr binding proteins and methods of use
US10815311B2 (en) 2018-09-25 2020-10-27 Harpoon Therapeutics, Inc. DLL3 binding proteins and methods of use
EP3861016A2 (en) 2018-10-03 2021-08-11 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
ES2962578T3 (es) 2018-10-31 2024-03-19 Regeneron Pharma Método y sistema de identificación y cuantificación de una proteína
AU2019370339B2 (en) * 2018-11-01 2024-07-11 Shandong New Time Pharmaceutical Co., Ltd. Bispecific antibody and use thereof
JP7482866B2 (ja) 2018-11-19 2024-05-14 ビオラ・セラピューティクス・インコーポレイテッド 生物学的治療薬による疾患処置方法およびデバイス
US11249089B2 (en) 2018-12-12 2022-02-15 Regeneron Pharmaceuticals, Inc. System and method of analysis of a protein using liquid chromatography-mass spectrometry
SG11202105948TA (en) 2018-12-19 2021-07-29 Regeneron Pharma Bispecific anti-muc16 x anti-cd28 antibodies and uses thereof
CA3124168A1 (en) 2018-12-19 2020-06-25 Regeneron Pharmaceuticals, Inc. Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
EP4220173A3 (en) 2019-01-16 2023-10-18 Regeneron Pharmaceuticals, Inc. Methods for characterizing disulfide bonds
CN113660956B (zh) 2019-01-28 2024-10-29 Ab诊疗公司 双特异性抗体及其用途
US20220106398A1 (en) * 2019-02-08 2022-04-07 Igm Biosciences, Inc. Anti-gitr antigen-binding domains and uses thereof
MA54945A (fr) 2019-02-12 2021-12-22 Regeneron Pharma Compositions et procédés d'utilisation d'anticorps bispécifiques pour lier un complément et un antigène cible
EP3932946A4 (en) * 2019-02-25 2023-03-22 Pharmabcine Inc. ANTI-ANG2 ANTIBODIES AND ITS USE
AU2020232605A1 (en) 2019-03-01 2021-10-21 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
KR20250143873A (ko) * 2019-03-08 2025-10-02 제넨테크, 인크. 세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
US11912767B2 (en) 2019-03-22 2024-02-27 Regeneron Pharmaceuticals, Inc. EGFR × CD28 multispecific antibodies
TW202039578A (zh) 2019-03-29 2020-11-01 荷蘭商美勒斯公司 Cd3結合分子
MA55551A (fr) * 2019-04-04 2022-02-09 Janssen Biotech Inc Anticorps anti-hla-c et leurs utilisations
CR20210500A (es) 2019-04-05 2021-11-05 Teneobio Inc Anticuerpos de cadena pesada que se unen al psma
US11613576B2 (en) 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
KR20220007586A (ko) 2019-05-13 2022-01-18 리제너론 파마슈티칼스 인코포레이티드 개선된 경쟁적 리간드 결합 검정
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN119874917A (zh) * 2019-06-07 2025-04-25 阿迪马布有限责任公司 工程化的pH依赖性抗CD3抗体及其产生和使用方法
UA128906C2 (uk) 2019-06-14 2024-11-20 Тенеобіо, Інк. Поліспецифічні антитіла, що містять тільки важкі ланцюги, які зв'язуються з cd22 та cd3
CN116987197A (zh) * 2019-06-20 2023-11-03 成都恩沐生物科技有限公司 共价多特异性抗体
US20200399372A1 (en) 2019-06-21 2020-12-24 Regeneron Pharmaceuticals, Inc. Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
MX2022001721A (es) 2019-08-15 2022-03-11 Genmab As Composiciones farmaceuticas que comprenden anticuerpos biespecificos dirigidos contra cd3 y cd20 y sus usos.
WO2021030680A1 (en) * 2019-08-15 2021-02-18 Regeneron Pharmaceuticals, Inc. Multispecific antigen-binding molecules for cell targeting and uses thereof
CN112390882A (zh) * 2019-08-19 2021-02-23 杨洋 靶向cd3和cd20的双特异性抗体及其应用
RU2738802C1 (ru) * 2019-08-21 2020-12-17 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Определяющие комплементарность участки для связывания cd3 и содержащая их биспецифическая антигенсвязывающая молекула
KR20220066393A (ko) 2019-09-24 2022-05-24 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
US12297451B1 (en) 2019-10-25 2025-05-13 Regeneron Pharmaceuticals, Inc. Cell culture medium
AU2020394428B2 (en) 2019-11-25 2025-11-20 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous emulsions
CA3160352A1 (en) 2019-12-06 2021-06-10 Israel Lowy Methods of treating multiple myeloma with bispecific anti-bcma x anti-cd3 antibodies
CA3159586A1 (en) 2019-12-06 2021-06-10 Regeneron Pharmaceuticals, Inc. Anti-vegf protein compositions and methods for producing the same
TW202135860A (zh) 2019-12-10 2021-10-01 美商再生元醫藥公司 含有抗ｃｄ２０ｘ抗ｃｄ３雙特異性抗體之穩定調配物
GB201918230D0 (en) 2019-12-11 2020-01-22 Prec Therapeutics Ltd Antibodies and their uses
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
AU2020403145B2 (en) 2019-12-13 2025-06-26 Genentech, Inc. Anti-Ly6G6D antibodies and methods of use
AU2021209866B2 (en) 2020-01-21 2023-07-06 Regeneron Pharmaceuticals, Inc. Deglycosylation methods for electrophoresis of glycosylated proteins
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
CN115768463A (zh) 2020-02-21 2023-03-07 哈普恩治疗公司 Flt3结合蛋白及使用方法
US12435155B2 (en) 2020-02-21 2025-10-07 Macrogenics, Inc. CD137 binding molecules and uses thereof
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN115894703A (zh) 2020-04-29 2023-04-04 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
CA3180569A1 (en) 2020-05-01 2021-11-04 Regeneron Pharmaceuticals, Inc. Neutralizing antibody assay for therapeutic proteins
JP2023525034A (ja) 2020-05-08 2023-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆトラップおよびミニトラップならびに眼障害およびがんの治療方法
JP2023524149A (ja) 2020-05-08 2023-06-08 ジェンマブ エー／エス Ｃｄ３およびｃｄ２０に対する二重特異性抗体
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
PE20230389A1 (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de cd3 y usos de estas
WO2021252917A2 (en) 2020-06-11 2021-12-16 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
JP7741111B2 (ja) 2020-06-19 2025-09-17 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｃｄ３及びｃｄ１９に結合する抗体
KR102825424B1 (ko) * 2020-07-10 2025-06-27 한양대학교 산학협력단 SARS-CoV-2 및 면역세포 수용체에 결합하는 이중특이적 항체 및 이를 포함하는 약학 조성물
KR20230166150A (ko) 2020-08-19 2023-12-06 젠코어 인코포레이티드 항-cd28 조성물
CN112062855B (zh) * 2020-08-26 2024-08-30 北京天诺健成医药科技有限公司 一种含有衔接器的药物治疗剂的开发和应用
MX2023002417A (es) 2020-08-31 2023-03-22 Regeneron Pharma Estrategias de suministro de asparagina para mejorar el rendimiento del cultivo celular y mitigar las variantes de secuencia de asparagina.
JP2023541858A (ja) 2020-09-10 2023-10-04 ジェンマブ エー／エス 慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
MX2023002542A (es) 2020-09-10 2023-03-15 Genmab As Anticuerpo biespecifico contra cumulo de difirenciacion 3 (cd3) y cumulo de difirenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma difuso de celulas b grandes.
BR112023004321A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma de célula b grande difusa em um sujeito humano
BR112023004351A2 (pt) 2020-09-10 2023-04-04 Genmab As Método para tratar linfoma folicular em um sujeito humano
BR112023004216A2 (pt) 2020-09-10 2023-04-11 Genmab As Método para tratar linfoma folicular em um sujeito humano
IL301242A (en) * 2020-09-11 2023-05-01 Janssen Biotech Inc Multi-specific immune targeting molecules and uses thereof
WO2022056197A1 (en) 2020-09-11 2022-03-17 Janssen Biotech, Inc. Immune targeting molecules and uses thereof
TW202227495A (zh) 2020-09-11 2022-07-16 美商健生生物科技公司 用於調節β鏈介導之免疫的方法及組成物
MX2023003214A (es) 2020-09-18 2023-05-24 Regeneron Pharma Moleculas de union al antigeno que se unen a cd38 y/o cd28 y usos de las mismas.
US20230374160A1 (en) 2020-10-02 2023-11-23 Regeneron Pharmaceuticals, Inc. Combination of antibodies for treating cancer with reduced cytokine release syndrome
KR102725210B1 (ko) * 2020-10-05 2024-11-04 한양대학교 산학협력단 안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
MX2023005130A (es) 2020-11-04 2023-05-25 Genentech Inc Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
CN118878694A (zh) * 2020-11-23 2024-11-01 康诺亚生物医药科技（成都）有限公司 一种双特异性抗体及其用途
IL303027A (en) 2020-11-25 2023-07-01 Regeneron Pharma Sustained release formulations by creating a non-aqueous membrane emulsion
EP4262757A1 (en) 2020-12-17 2023-10-25 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
CN114656562B (zh) * 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
JP2024503408A (ja) 2021-01-20 2024-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 細胞培養におけるタンパク質力価の改善方法
HUE071594T2 (hu) 2021-01-28 2025-09-28 Regeneron Pharma Készítmények és módszerek a citokinfelszabadulási szindróma kezelésére
AU2022230987A1 (en) 2021-03-03 2023-08-31 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
AU2022243005A1 (en) 2021-03-26 2023-10-05 Regeneron Pharmaceuticals, Inc. Methods and systems for developing mixing protocols
JP2024517535A (ja) 2021-04-30 2024-04-23 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃｄ２０／抗ｃｄ３二重特異性抗体と抗ｃｄ７９ｂ抗体薬物コンジュゲートを用いた併用治療の投与
WO2022228706A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for treatment with anti-cd20/anti-cd3 bispecific antibody
EP4337330A1 (en) 2021-05-14 2024-03-20 Genentech, Inc. Methods for treatment of cd20-positive proliferative disorder with mosunetuzumab and polatuzumab vedotin
EP4348234A1 (en) 2021-06-01 2024-04-10 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
EP4355778A1 (en) 2021-06-17 2024-04-24 Boehringer Ingelheim International GmbH Novel tri-specific binding molecules
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2023028612A2 (en) 2021-08-27 2023-03-02 Board Of Regents, The University Of Texas System Anti-tslpr (crlf2) antibodies
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
CN117940457A (zh) * 2021-09-13 2024-04-26 山东先声生物制药有限公司 抗人cd3抗体及其应用
KR20240058201A (ko) 2021-09-20 2024-05-03 리제너론 파마슈티칼스 인코포레이티드 항체 이질성을 제어하는 방법
AU2022355388A1 (en) * 2021-09-30 2024-03-14 Betta Pharmaceuticals Co., Ltd Bispecific antibody and application thereof
CN118076885A (zh) 2021-10-07 2024-05-24 里珍纳龙药品有限公司 pH计校准与校正
WO2023059800A2 (en) 2021-10-07 2023-04-13 Regeneron Pharmaceuticals, Inc. Systems and methods of ph modeling and control
WO2023076340A1 (en) 2021-10-26 2023-05-04 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
KR20240109255A (ko) 2021-10-28 2024-07-10 라이엘 이뮤노파마, 인크. 세포를 생성하는 방법
US20250082777A1 (en) 2022-01-10 2025-03-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
US20250154275A1 (en) * 2022-01-20 2025-05-15 Shanghai Junshi Biosciences Co., Ltd. Anti-cd3 and anti-cd20 bispecific antibody and use thereof
EP4472646A1 (en) 2022-02-01 2024-12-11 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
TW202346856A (zh) 2022-03-18 2023-12-01 美商里珍納龍藥品有限公司 分析多肽變體的方法及系統
AU2023238766A1 (en) 2022-03-23 2024-07-25 F. Hoffmann-La Roche Ag Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
WO2023179716A1 (zh) * 2022-03-23 2023-09-28 上海济煜医药科技有限公司 一种抗cd3抗体、其制备方法及应用
CA3245704A1 (en) 2022-03-29 2023-10-05 Ngm Biopharmaceuticals, Inc. ILT3 AND CD3 LINKING AGENTS AND THEIR METHODS OF USE
US20250222027A1 (en) 2022-04-01 2025-07-10 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
KR20250004700A (ko) 2022-04-11 2025-01-08 리제너론 파마슈티칼스 인코포레이티드 보편적 종양 세포 사멸을 위한 조성물 및 방법
WO2023198839A2 (en) 2022-04-13 2023-10-19 Genmab A/S Bispecific antibodies against cd3 and cd20
CA3255366A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions based on bispecific anti-CD20/anti-CD3 antibodies and methods of use
WO2023214960A1 (en) 2022-05-02 2023-11-09 Regeneron Pharmaceuticals, Inc. Biochemical assays for therapeutic proteins
JP2025519057A (ja) 2022-05-18 2025-06-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｃｄ３８及び４－１ｂｂに結合する多重特異性抗原結合分子、並びにその使用
WO2023235805A2 (en) * 2022-06-01 2023-12-07 The Wistar Institute Of Anatomy And Biology Dna-encoded bispecific antibodies targeting carbonic anhydrase 9 and methods of use in cancer therapeutics
WO2024012513A1 (en) * 2022-07-13 2024-01-18 Hansoh Bio Llc Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
CN119816520A (zh) 2022-08-02 2025-04-11 瑞泽恩制药公司 使用双特异性抗psma×抗cd28抗体与抗pd-1抗体组合来治疗转移性去势抵抗性前列腺癌的方法
WO2024044655A1 (en) 2022-08-24 2024-02-29 Sana Biotechnology, Inc. Delivery of heterologous proteins
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024088987A1 (en) 2022-10-26 2024-05-02 F. Hoffmann-La Roche Ag Combination therapy for the treatment of cancer
CN116023499B (zh) * 2022-10-26 2024-01-23 北京力邦生物医药科技有限公司 一种针对cd3和cd20的双特异性抗体
WO2024119157A1 (en) 2022-12-02 2024-06-06 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
US20250076310A1 (en) 2022-12-08 2025-03-06 Regeneron Pharmaceuticals, Inc. Methods to characterizing a fragment crystallizable domain of a bispecific antibody
CN120418653A (zh) 2022-12-16 2025-08-01 里珍纳龙药品有限公司 评估色谱柱完整性的方法和系统
EP4655595A1 (en) 2023-01-25 2025-12-03 Regeneron Pharmaceuticals, Inc. Mass spectrometry-based characterization of antibodies co-expressed in vivo
TW202445135A (zh) 2023-01-25 2024-11-16 美商再生元醫藥公司 液態蛋白質組成物穩定性之建模方法
AU2024223918A1 (en) 2023-02-17 2025-09-11 Regeneron Pharmaceuticals, Inc. Induced nk cells responsive to cd3/taa bispecific antibodies
EP4669963A2 (en) 2023-02-22 2025-12-31 Regeneron Pharmaceuticals, Inc. SYSTEM FITNESS PARAMETERS AND COLUMN AGING
KR20250156813A (ko) 2023-03-13 2025-11-03 리제너론 파아마슈티컬스, 인크. 이중특이성 항-CD22 x 항-CD28 분자를 이용한 암 치료 방법
TW202504915A (zh) 2023-04-13 2025-02-01 丹麥商珍美寶股份有限公司 以抗ｃｄ３及ｃｄ２０之雙特異性抗體治療淋巴瘤之方法
WO2024220597A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Digital droplet based assay for detecting replication competent lentiviral vector
AU2024265540A1 (en) 2023-05-01 2025-10-30 Regeneron Pharmaceuticals, Inc. Multidose antibody drug products using phenol or benzyl alcohol
TW202508630A (zh) 2023-05-15 2025-03-01 丹麥商珍美寶股份有限公司 治療表現ｃｄ２０之ｂ細胞癌症之方法
TW202509073A (zh) 2023-05-15 2025-03-01 丹麥商珍美寶股份有限公司 高度純化之依可利單抗組成物
WO2024243340A1 (en) 2023-05-23 2024-11-28 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
TW202519547A (zh) 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1x4-1BB抗體及其使用方法
TW202519559A (zh) 2023-07-10 2025-05-16 美商再生元醫藥公司 雙特異性PD-L1xCD28抗體及其使用方法
US20250086164A1 (en) 2023-09-08 2025-03-13 Regeneron Pharmaceuticals, Inc. Methods and systems for assessing chromatographic column integrity
WO2025064403A2 (en) 2023-09-18 2025-03-27 Regeneron Pharmaceuticals, Inc. Methods and systems for developing chromatography protocols
TW202532098A (zh) 2023-09-29 2025-08-16 美商再生元醫藥公司 使用控制成核之冷凍乾燥
WO2025085594A1 (en) 2023-10-18 2025-04-24 Regeneron Pharmaceuticals, Inc. Rapid purification of monoclonal antibody from in-process upstream cell culture material
TW202535934A (zh) 2023-11-02 2025-09-16 美商再生元醫藥公司 利用應力來降低脂酶活性的方法
WO2025111473A1 (en) 2023-11-21 2025-05-30 Regeneron Pharmaceuticals, Inc. Covalently surface modified adeno-associated virus production by in vitro conjugation, and purification of covalently surface modified adeno-associated virus
WO2025109119A1 (en) 2023-11-22 2025-05-30 Priothera Sas Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
WO2025131075A1 (zh) * 2023-12-21 2025-06-26 上海君实生物医药科技股份有限公司 抗cd3和抗cd3多特异性抗体及用途
US20250242018A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025160324A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025166281A1 (en) 2024-02-01 2025-08-07 Regeneron Pharmaceuticals, Inc. Platform for charge-detection mass spectrometry analysis of aavs
WO2025175164A1 (en) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods
US20250276092A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
WO2025194043A1 (en) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations
US20250297006A1 (en) 2024-03-20 2025-09-25 Regeneron Pharmaceuticals, Inc. Masked Multispecific Antigen-Binding Molecules with Cleavable Linkers
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025259840A1 (en) 2024-06-13 2025-12-18 Regeneron Pharmaceuticals, Inc. Methods and systems for scaled chromatography

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361549A (en) 1979-04-26 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells, and methods of preparing same
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DK0590058T3 (da) 1991-06-14 2004-03-29 Genentech Inc Humaniseret heregulin-antistof
MX9204374A (es) 1991-07-25 1993-03-01 Idec Pharma Corp Anticuerpo recombinante y metodo para su produccion.
DK0752248T3 (da) 1992-11-13 2000-11-13 Idec Pharma Corp Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DK0826696T3 (da) 1996-09-03 2002-09-23 Gsf Forschungszentrum Umwelt Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
EA004107B1 (ru) 1998-08-11 2003-12-25 Айдек Фармацевтикалс Корпорэйшн Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20
US6224866B1 (en) 1998-10-07 2001-05-01 Biocrystal Ltd. Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
NZ514914A (en) 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
ITMI991299A1 (it) 1999-06-11 2000-12-11 Consiglio Nazionale Ricerche Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CN101914158A (zh) 2002-02-14 2010-12-15 免疫医疗公司 抗cd 20抗体及其融合蛋白和使用方法
EP1400534B1 (en) 2002-09-10 2015-10-28 Affimed GmbH Human CD3-specific antibody with immunosuppressive properties
CN103709250B (zh) * 2002-10-17 2016-08-10 根马布股份公司 抗cd20的人单克隆抗体
US8084582B2 (en) 2003-03-03 2011-12-27 Xencor, Inc. Optimized anti-CD20 monoclonal antibodies having Fc variants
EP1626993B1 (en) 2003-05-09 2015-03-11 Duke University Cd20-specific antibodies and methods of employing same
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
NZ543202A (en) 2003-05-31 2008-04-30 Micromet Ag Pharmaceutical composition comprising a bispecific antibody for epcam
CA2523716C (en) * 2003-05-31 2014-11-25 Micromet Ag Human anti-human cd3 binding molecules
CN1845755A (zh) 2003-08-29 2006-10-11 健泰科生物技术公司 眼部疾病的抗cd－20治疗
PL1673398T3 (pl) * 2003-10-16 2011-05-31 Amgen Res Munich Gmbh Multispecyficzne deimmunizowane cząsteczki wiążące CD3
US20050191297A1 (en) 2003-12-19 2005-09-01 Genentech, Inc. Detection of CD20 in transplant rejection
US7339198B2 (en) 2004-01-16 2008-03-04 Yu-Nung Shen Light-emitting diode chip package body and packaging method thereof
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
US20050271658A1 (en) 2004-05-05 2005-12-08 Genentech, Inc. Preventing autoimmune disease
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
DOP2005000108A (es) 2004-06-04 2007-06-15 Genentech Inc Method for treating lupus
US20060110387A1 (en) 2004-10-05 2006-05-25 Genentech, Inc. Method for treating vasculitis
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
RU2007143302A (ru) 2005-04-22 2009-05-27 Дженентек, Инк. (Us) Способ лечения деменции или болезни альцгеймера антителами к cd20
WO2006130458A2 (en) 2005-06-02 2006-12-07 Astrazeneca Ab Antibodies directed to cd20 and uses thereof
EP2500358A3 (en) * 2005-08-19 2012-10-17 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
NZ597168A (en) * 2005-08-19 2013-07-26 Abbott Lab Dual variable domain immunoglobin and uses thereof
ES2616316T3 (es) * 2005-10-11 2017-06-12 Amgen Research (Munich) Gmbh Composiciones que comprenden anticuerpos específicos para diferentes especies y usos de los mismos
EP1820513A1 (en) * 2006-02-15 2007-08-22 Trion Pharma Gmbh Destruction of tumor cells expressing low to medium levels of tumor associated target antigens by trifunctional bispecific antibodies
CN101454345B (zh) 2006-06-02 2012-08-08 瑞泽恩制药公司 人il-6受体的高亲和力抗体
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
RS53008B2 (sr) * 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Interspecijski specifičan cd3-epsilon vezujući domen
CA2682626A1 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific bispecific binders
PT2520590T (pt) * 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
DK2178916T3 (en) * 2007-07-31 2015-01-12 Regeneron Pharma Human antibodies to human cd20 and method thereof for use
MY153781A (en) 2007-08-10 2015-03-13 Regeneron Pharma High affinity human antibodies to human nerve growth factor
EP2197918B1 (en) * 2007-09-05 2013-12-18 F. Hoffmann-La Roche AG Combination therapy with type i and type ii anti-cd20 antibodies
WO2009106096A1 (en) * 2008-02-27 2009-09-03 Fresenius Biotech Gmbh Treatment of resistant tumors with trifunctional antibodies
AU2009313039B2 (en) 2008-11-07 2015-06-18 Amgen Research (Munich) Gmbh Treatment of pediatric acute lymphoblastic leukemia
WO2010151792A1 (en) * 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
MX341796B (es) 2009-12-29 2016-09-02 Emergent Product Dev Seattle Proteinas de union heterodimericas y usos de las mismas.
WO2011097603A1 (en) 2010-02-08 2011-08-11 Regeneron Pharmaceuticals, Inc. Common light chain mouse
CN102250245B (zh) * 2010-05-27 2014-05-14 四川大学 抗b细胞淋巴瘤的双特异性抗体及其用途
ES2693232T3 (es) 2010-11-30 2018-12-10 Chugai Seiyaku Kabushiki Kaisha Agente terapéutico que induce citotoxicidad
CN107474133B (zh) * 2011-02-08 2021-10-15 米迪缪尼有限公司 特异性结合金黄色葡萄球菌α毒素的抗体以及使用方法
CN104640562A (zh) 2012-07-13 2015-05-20 酵活有限公司 包含抗-cd3构建体的双特异性不对称异二聚体
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
PT3016681T (pt) 2013-07-05 2020-03-26 Genmab As Anticorpos humanizados ou quiméricos cd3
RU2016104130A (ru) 2013-07-12 2017-08-17 Займворкс Инк. Биспецифичные конструкции, связывающие антигены cd3 и cd19
PT3083689T (pt) 2013-12-17 2020-08-27 Genentech Inc Anticorpos anti-cd3 e métodos de utilização
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
TWI754319B (zh) 2014-03-19 2022-02-01 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物

Also Published As

Publication number Publication date
SI2897981T1 (sl) 2023-07-31
PL3778641T3 (pl) 2024-04-02
TW202039579A (zh) 2020-11-01
SG11201501269XA (en) 2015-03-30
CL2020003179A1 (es) 2021-04-30
EP2897981A1 (en) 2015-07-29
CN110041429B (zh) 2023-01-03
IL237301A0 (en) 2015-04-30
TWI618716B (zh) 2018-03-21
FI3778641T3 (fi) 2023-12-15
ZA201501097B (en) 2024-06-26
RS65123B1 (sr) 2024-02-29
CN113980132B (zh) 2025-07-04
JO3716B1 (ar) 2021-01-31
PH12015500328B1 (en) 2021-05-05
HUE063215T2 (hu) 2024-01-28
CA3135724C (en) 2025-07-08
JOP20200237A1 (ar) 2022-10-30
HRP20230844T1 (hr) 2023-11-10
DK2897981T3 (da) 2023-07-10
US11072656B2 (en) 2021-07-27
LT3778641T (lt) 2023-12-11
US20180215823A1 (en) 2018-08-02
SG10202111095XA (en) 2021-11-29
KR102163136B1 (ko) 2020-10-12
AU2013318059C1 (en) 2020-10-15
DK3778641T3 (da) 2023-12-11
HK1212996A1 (en) 2016-06-24
CO7400860A2 (es) 2015-09-30
SG10201704833WA (en) 2017-07-28
PT2897981T (pt) 2023-06-27
JP7727047B2 (ja) 2025-08-20
US20140088295A1 (en) 2014-03-27
CA3253502A1 (en) 2025-02-24
WO2014047231A1 (en) 2014-03-27
ES2968913T3 (es) 2024-05-14
JOP20200236A1 (ar) 2017-06-16
ES2948807T3 (es) 2023-09-19
DK3778641T5 (da) 2024-08-19
IL268369A (en) 2019-09-26
JP7330228B2 (ja) 2023-08-21
SI3778641T1 (sl) 2024-01-31
EA033400B1 (ru) 2019-10-31
RS64378B1 (sr) 2023-08-31
TWI697502B (zh) 2020-07-01
SMT202300456T1 (it) 2024-01-10
CA2885156A1 (en) 2014-03-27
CA2885156C (en) 2021-12-07
CA3135724A1 (en) 2014-03-27
JP2015535828A (ja) 2015-12-17
CN110041429A (zh) 2019-07-23
JP6865324B2 (ja) 2021-04-28
JP2019214591A (ja) 2019-12-19
CN113980132A (zh) 2022-01-28
PL2897981T3 (pl) 2023-11-20
AU2020239677A1 (en) 2020-10-15
EA201590613A1 (ru) 2015-08-31
AU2018232926A1 (en) 2018-10-04
MX373931B (es) 2020-07-10
TWI688573B (zh) 2020-03-21
US9657102B2 (en) 2017-05-23
MY179577A (en) 2020-11-11
PH12019502070A1 (en) 2021-01-18
US20170320948A1 (en) 2017-11-09
KR20200116548A (ko) 2020-10-12
PT3778641T (pt) 2023-12-18
US20240352124A1 (en) 2024-10-24
PH12015500328A1 (en) 2015-03-30
AR092612A1 (es) 2015-04-29
EP4309740A2 (en) 2024-01-24
EP4309740A3 (en) 2024-06-05
TW201418282A (zh) 2014-05-16
MX2015003206A (es) 2015-07-14
LT2897981T (lt) 2023-07-10
BR112015005380B1 (pt) 2022-11-29
AU2020239677B2 (en) 2024-02-08
CN104640881A (zh) 2015-05-20
KR20150046789A (ko) 2015-04-30
DK2897981T5 (da) 2024-10-14
EP2897981B1 (en) 2023-06-07
TW201945398A (zh) 2019-12-01
JP2023100964A (ja) 2023-07-19
CL2017001729A1 (es) 2018-03-16
CL2015000713A1 (es) 2015-07-10
EP3778641A1 (en) 2021-02-17
EP3778641B1 (en) 2023-11-08
BR112015005380A2 (pt) 2017-08-08
JP2025166058A (ja) 2025-11-05
AU2013318059A1 (en) 2015-04-09
PH12019502070B1 (en) 2024-02-28
NZ742078A (en) 2020-01-31
CN104640881B (zh) 2021-11-05
JP2021130701A (ja) 2021-09-09
TW201809007A (zh) 2018-03-16
FI2897981T3 (fi) 2023-07-04
HRP20240149T1 (hr) 2024-04-12
UY35042A (es) 2014-04-30
IL237301B (en) 2020-08-31
JP2024109678A (ja) 2024-08-14
MX2020004119A (es) 2020-08-10
JP6923292B2 (ja) 2021-08-18
AU2018232926B2 (en) 2020-06-25
ZA201705757B (en) 2024-06-26
JP7490857B2 (ja) 2024-05-27
IL268369B (en) 2021-02-28
SMT202300226T1 (it) 2023-09-06
KR102470709B1 (ko) 2022-11-28
HUE065481T2 (hu) 2024-05-28
JP2021020961A (ja) 2021-02-18
US11155621B2 (en) 2021-10-26
AU2013318059B2 (en) 2018-10-18
US20220144947A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
NZ706232A (en) Anti-cd3 antibodies and uses thereof
IN2014MN00873A (enExample)
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
NZ716369A (en) Anti-ox40 antibodies and methods of using the same
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
ECSP11011239A (es) Proteínas ligadoras il-1
NZ726258A (en) Antibodies and uses thereof to detect folate receptor 1
NZ720765A (en) Antibodies and methods of use
TR201815254T4 (tr) Tl1a'ya bağlanan anti̇korlar ve bunlarin kullanimlari
IN2014MN02293A (enExample)
EA201691858A1 (ru) Композиции антител для лечения опухолей
AU2012307816A8 (en) Anti-alphabeta TCR antibody
WO2014012085A3 (en) Bispecific asymmetric heterodimers comprising anti-cd3 constructs
EA201490745A1 (ru) Полипептиды антител, которые вызывают антагонизм cd40l
MX2014002097A (es) Anticuerpos bioespecificos especificos para antigenos que activan celulas t y un antigeno tumoral y metodos de uso.
ES2639026T3 (es) Anticuerpos totalmente humanos específicos para CADM1
NZ701444A (en) Antibodies to matrix metalloproteinase 9
NZ588713A (en) Antibodies to receptor of advanced glycation end products (rage) and uses thereof
EA201490053A1 (ru) Антитела, которые связываются с ox40, и их применение
TN2014000120A1 (en) Cd27l antigen binding proteins
NZ611428A (en) Novel modulators and methods of use
NZ597447A (en) Humanised antibodies to toll-like receptor 2 and uses thereof
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
NZ599097A (en) Chimeric antibodies specific for cd151 and use thereof in the treatment of cancer
RU2012113360A (ru) Вариабельные домены легкой и тяжелой цепи мышиного моноклонального антитела против фактора некроза опухоли альфа (фно-альфа) человека (варианты), антигенсвязывающий фрагмент (fab) против фно-альфа человека, содержащий указанные домены (варианты)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2020 BY ANAQUA SERVICES

Effective date: 20190820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2021 BY ANAQUA SERVICES

Effective date: 20200819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2022 BY ANAQUA SERVICES

Effective date: 20210819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2023 BY ANAQUA SERVICES

Effective date: 20220819

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2024 BY ANAQUA SERVICES

Effective date: 20230823

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2025 BY ANAQUA SERVICES

Effective date: 20240820

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 19 SEP 2026 BY ANAQUA SERVICES

Effective date: 20250820